ORIGINAL ARTICLE |
|
Year : 2020 | Volume
: 33
| Issue : 2 | Page : 599-603 |
|
Aflibercept vs ranibizumab in management of diabetic macular edema
Khaled E Ahmed, Ahmed I Basiony, Eman S Hamad
Department of Ophthalmology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Correspondence Address:
Eman S Hamad Shebin El Kom, Menoufia Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_302_19
|
|
Objective
The aim was to compare the efficacy of intravitreal injection of aflibercept and ranibizumab in the treatment of diabetic macular edema (DME).
Background
Diabetic retinopathy is a microangiopathy of the retina from which nearly all persons with diabetes eventually suffer. DME is one of its complications that threaten the patient's vision.
Patients and methods
This is a randomized prospective study. Fifty eyes with DME were divided into two groups (each containing 25 eyes). Eyes in group I were treated with intravitreal injection of aflibercept, and eyes in group II were treated with intravitreal injection of ranibizumab. All eyes had three successive injections. The outcomes were visual acuity and central subfield macular thickness.
Results
The mean baseline best-corrected visual acuity (BCVA) in group I was 0.65 ± 0.12 μm and in group II was 0.63 ± 0.19 μm (P = 0.72). After 3 months, the mean BCVA in group I improved to 0.34 ± 0.16 and in group II improved to 0.44 ± 0.21 (P = 0.10). At the end of sixth month, the BCVA was 0.42 ± 0.18 in group I and0.47 ± 0.18 in group II (P = 0.23). The mean baseline central subfield thickness (CST) of eyes in group I was 523.8 ± 105.3 μm and in group II was 477.4 ± 143.6 μm (P = 0.11). After 3 months, the mean CST in eyes of group I decreased to 348.04 ± 98.4 μm, whereas in eyes of group II, the mean CST decreased to 377.5 ± 115.7 μm (P = 0.031). After 6 months, the mean CST in the eyes of the group I became 373.6 ± 139.8 μm, whereas in eyes of group II became 371.7 ± 102.3 μm (P = 0.96).
Conclusion
Aflibercept and ranibizumab have the same efficacy in the treatment of DME.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|